In the trial, Wegovy decreased relative risk by 20% of a composite primary endpoint measure which included death from cardiovascular causes, non-fatal myocardial infarction and non-fatal stroke
In a cohort study involving 1819 participants from NHANES data (20112018), aspirin users had a 35% lower risk of all-cause death (HR 0.647, 95% CI 0.4890.857) compared to non-users, suggesting aspirins potential role in improving overall survival among cancer patients
So the potential for growth is actually similar again as a percentage
Future studies should address the effects of changes in ASC subtypes, immune cells, and adipocyte functions, and particularly the expression of receptors that regulate lipid removal in aging adipose tissue
The drugs dual mechanism of action targeting appetite regulation and metabolism positions it as a powerful ally in the pursuit of weight loss for effective results